The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one-stage clotting assay

Factor VIII coagulant (FVIII:C) levels measured in patients receiving ReFacto® (B‐domain‐deleted recombinant FVIII) using chromogenic substrate assay (CSA) and one‐stage clotting assay (OSA) have frequently shown discrepancies, and the use of the ReFacto Laboratory Standard (RLS) has therefore been...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Haemophilia : the official journal of the World Federation of Hemophilia 2011-09, Vol.17 (5), p.e958-e962
Hauptverfasser:	POUPLARD, C., CARON, C., AILLAUD, M. F., TERNISIEN, C., DESCONCLOIS, C., DUBANCHET, A., SOBAS, F.
Format:	Artikel
Sprache:	eng
Schlagworte:	assay discrepancies Biological Assay Blood Coagulation Tests - standards chromogenic assay Chromogenic Compounds factor VIII Factor VIII - therapeutic use France Hematologic Tests - methods Hematologic Tests - standards Hemophilia A - blood Hemophilia A - drug therapy Humans Infusions, Intravenous one-stage clotting assay Peptide Fragments - blood Peptide Fragments - therapeutic use recombinant B-domain-deleted FVIII Reference Standards
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!